Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 18.48
Key Takeaways
Risk factor
Good trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Jiangsu Aidea Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products. It offers folium sennae granules, powdered bacillus tablets, clindamycin hydrochloride capsules, sodium bicarbonate tablets, nitrendipine tablets, metronidazole tablets, compound gentamycin sulfate and procaine hydrochloride sulfate granules, and cefradine capsules, as well as raw materials. The company was founded in 2009 and is based in Yangzhou, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Data is available to registered users only
